Trastuzumab duocarmazine
This product is an antibody–drug conjugate (ADC) combining trastuzumab with a cleavable linker and duocarmycin payload. It specifically targets HER2-expressing cancers, delivering potent cytotoxic activity while minimizing systemic toxicity.
Key Features and Benefits
-
HER2 Targeting: Leverages trastuzumab’s strong HER2 specificity for targeted therapy.
-
ADC Design: Couples antibody with duocarmycin prodrug via a cleavable linker.
-
Potent Payload: Releases active duocarmycin inside HER2-positive cells.
-
Targeted Therapy: Reduces off-target toxicity compared to traditional chemotherapy.
-
Clinical Potential: Evaluated in breast, endometrial, and other HER2-expressing cancers.
Applications
-
Oncology Research: Investigates targeted therapy for HER2-positive cancers.
-
ADC Development: Demonstrates cleavable linker technology with potent DNA-alkylating payloads.
-
Drug Discovery: Provides insights into HER2 biology and ADC design.
-
Translational Medicine: Supports therapeutic development in breast and endometrial cancer.
Storage and Handling
-
Storage: Store at –80 °C in sealed vials for long-term stability.
-
Handling: Thaw gently on ice; avoid repeated freeze–thaw cycles.
This product integrates trastuzumab targeting with a cleavable duocarmycin payload, specifically offering potent activity against HER2-expressing tumors.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.